Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study
Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Séverine Vermeire(KU Leuven), Zijiang Yang(Henan Medical University), William J. Sandborn(University of San Diego), Julián Panés(Hospital Clínic de Barcelona), Brian G. Feagan(Western University), Colleen Marano(Johnson & Johnson (United States)), Gary R. Lichtenstein(University of Pennsylvania), Christopher D. O’Brien(Cedars-Sinai Medical Center), Kirk Bertelsen(Fate Therapeutics (United States)), Philippe Szapary(Cedars-Sinai Medical Center), Jewel Johanns(Johnson & Johnson (United States)), Richard Strauß(Hennepin County Medical Center), Hongyan Zhang(Northwest A&F University)
Cited by 115
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k